ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer

The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).

Trial Details

NCT ID
NCT06498479
Phase
PHASE3
Sponsor
Hansoh BioMedical R&D Company
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • HS-20093
  • Topotecan
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Harbin, Heilongjiang, China|45.75,126.65
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Changchun, Jilin, China|43.88,125.32278
  • Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

  • Male or female subjects ≥18 years of age.
  • Histologically or cytologically confirmed SCLC.
  • Subjects who progressed on or after first-line platinum-based regimens.
  • Has at least 1 measurable lesion as defined per RECIST 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →